ViroGates publishes its financial calendar for 2025
Company Announcement no. 13/2024 (December 19, 2024)
BIRKERØD, DENMARK—ViroGates A/S (“ViroGates” or the “Company”), a medical technology company developing blood tests for measuring the level of inflammation in individuals in health clinics and hospitals, today publishes the financial calendar for 2025 with the following key dates:
| 20 March 2025 | Annual Report 2024 |
| 3 April 2025 | Deadline for submission of business to be transacted at the 2025 Annual General Meeting |
| 24 April 2025 | Annual General Meeting |
| 1 May 2025 | Interim Report Q1 2025 |
| 21 August 2025 | Interim Report H1 2025 |
| 6 November 2025 | Interim Report Q1-Q3 2025 |
The interim and annual financial reports will be available on ViroGates’ website (www.virogates.com) immediately after release.
ViroGates encourages all shareholders to sign up to receive relevant shareholder information at its shareholder portal
(https://www.virogates.com/virogates-shareholder-portal).
Written requests to have specific business transacted at the Annual General Meeting will be included in the agenda if received by the company no later than 3rd April 2025 via email to jk@virogates.com or jbj@virogates.com.
For further information, please contact:
ViroGates A/S:
CEO, Jakob Knudsen
Tel. (+45) 2226 1355, email: jk@virogates.com
Certified Advisor:
Västra Hamnen Corporate Finance
Per Lönn
Tel. (+46) 40 200 250, email: ca@vhcorp.se
About ViroGates
ViroGates A/S is an international medical technology company that develops blood tests to measure inflammation in individuals in health clinics and improve patient care in hospitals. ViroGates markets its blood test products under the suPARnostic® brand.
The company was founded in 2000. Headquartered in Denmark, ViroGates’ sales force covers Spain, France, and Benelux, while distributors serve other markets. ViroGates’ shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit www.virogates.com.